Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03913130 · ClinicalTrials.gov registry record · Phase 1
Extension Study to Study PQ-110-001 (NCT03140969)
A Phase 1 study, sponsored by Laboratoires Thea.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03913130 is a Phase 1 study that was terminated before completion, run by Laboratoires Thea. The registered enrollment target is 9 participants.
The verdict
NCT03913130, a Phase 1 study, was terminated before completion, sponsored by Laboratoires Thea.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.
Interventions
- DRUG QR-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-05-13 |
| Est. Completion | 2022-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03913130
The ClinicalTrials.gov registry entry for NCT03913130 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Laboratoires Thea, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QR-110 is the first listed.
NCT03913130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03913130 about?
NCT03913130 is a clinical study titled "Extension Study to Study PQ-110-001 (NCT03140969)". Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety,...
What is the current status of trial NCT03913130?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-05-13. Estimated completion is 2022-10-03.
What interventions are being tested in trial NCT03913130?
The interventions under investigation include: QR-110 (DRUG).
Who is sponsoring clinical trial NCT03913130?
This trial is sponsored by Laboratoires Thea, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.